Definium Therapeutics (DFTX) Change in Accured Expenses (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Change in Accured Expenses data on file, last reported at $3.0 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 325.28% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $10.3 million, a 129.64% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 92.01% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $3.0 million, up from $923000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for DFTX reached as high as $3.8 million in Q4 2024 and fell as low as -$2.7 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $997470.6 across 5 years, with a median of $990000.0 in 2024.
• Across the five-year window, Change in Accured Expenses surged 1677.23% in 2023 and plunged 484.5% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$1.0 million in 2022, then soared by 251.83% to $1.6 million in 2023, then soared by 140.23% to $3.8 million in 2024, then tumbled by 75.62% to $923000.0 in 2025, then jumped by 224.38% to $3.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $3.0 million in Q1 2026, $923000.0 in Q4 2025, and $3.4 million in Q3 2025.